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Abstract
           
            The implantable cardioverter-defibrillator (ICD) has become an integral part of treatment 
for a variety of patients with symptomatic, or at risk for, ventricular tachyarrhythmias. The ICD's 
effectiveness is attributed to its ability to promptly detect and terminate ventricular tachycardia 
(VT) and fibrillation (VF). The clinical trials that established the positive role of ICD therapy 
were based on patients who underwent some form of defibrillation testing at the time of 
implantation. Therefore, since its advent, intraoperative defibrillation testing of the ICD to 
assure reliable detection and termination of VT/VF has been a standard practice. But because of 
advances   in   defibrillator   and   lead   technology,   which   now   facilitates   successful   device 
implantation (i.e., low defibrillation energy requirement to allow for an adequate programmed 
safety margin) in the majority of patients, the necessity of defibrillation testing has been called 
into attention. Despite substantial progress, it is not altogether clear whether a wholesale 
abandonment of intraoperative ICD testing is appropriate at this point. We review pertinent data 
regarding pros and cons of ICD testing and offer a suggestion as to when, how, and who should 
test   ICDs.                                                                                    
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            Several clinical trials over the past decade have established the efficacy and benefit of the 
implantable cardioverter-defibrillator (ICD) in patients with documented1, as well as those at 
increased risk of developing2-4, sustained ventricular tachyarrhythmias. As a result ICD therapy 
has become standard therapy for a variety of patient groups5. Through its ability to detect and 
(promptly) terminate >95% of spontaneous episodes of ventricular tachycardia (VT) and 
ventricular fibrillation (VF), ICD therapy has been shown to reduce the risk of sudden death6 and 
overall mortality1-4. Such observations were based on patients who underwent some form of 
intraoperative testing1-4. Therefore, ICD testing at the time of device implantation to confirm 
proper detection and successful termination of induced VT/VF has been the standard of care for 
several years7-11. The amount of energy (Joules) needed to terminate VF is used to establish a 
given patient's defibrillation energy requirement (DER).                                                         
               Advances  in  defibrillator   technology,  most  notably  the  use  of   biphasic  shock 
waveforms12-15, now facilitate successful device implantation (i.e., DER that is at least 10 J 
lower  than  the  device's  maximum  output)  in  the  majority  of  cases16-19.   As  a  result,  some 
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investigators20  have recently questioned the necessity of ICD testing altogether, noting that, 
among other considerations, forfeiting ICD testing might lead to an increase in the use of ICDs 
by allowing non-electrophysiologists with reduced training requirements21, who may also be 
uncomfortable with ICD testing, to implant devices. Despite substantial improvement in device 
and lead technologies and the (probable) necessity to expand device therapy to a greater number 
of   patients,   current   data   do   not   support   wholesale   abandonment   of   ICD   testing19,22,23.
     
When   To   Test                                                                        
            Device testing at the time of implantation has been a mainstay of such therapy since the 
advent of the ICD. Unless there are specific contraindications to testing (Table 1), VF should be 
induced to ensure that the ICD can reliably sense, detect and terminate the arrhythmia with an 
adequate shock energy (see below). Some of the contraindications are absolute and unavoidable 
(e.g., known cavity thrombus), but others can be overcome (such as assuring the presence of 
anesthesia staff to facilitate testing). Among our cohort of 835 consecutive patients, testing was 
not performed in 203 (24%), of which ~70% were due to the presence of cavity thrombi or 
inadequate anticoagulation and intraoperative hypotension19. Other investigators have reported 
similar results22, and in general in up to a third of patients, testing may have to be postponed. 
Recently   some   have   postponed   intraoperative   testing   in   patients   undergoing   cardiac 
resynchronization therapy (CRT) devices for fear of coronary sinus lead dislodgment24, but we 
have not found this to be a significant problem among a cohort of >500 patients (unpublished 
observation). Patients who do not undergo intraoperative testing should be reassessed in the near 
future (usually 4 to 6 weeks) and testing reconsidered once the contraindications have been 
resolved.  
            With rare exceptions noninvasive postoperative testing of ICDs, either predischarge or 
several weeks post-implantation, may not be required25-29 unless there are specific circumstances 
in which an increase in DER is expected, most notably the addition of amiodarone therapy. 
Because amiodarone increases DER by as much as 50%30-33, and can also result in significant 
slowing of VT rate and, therefore, need for ICD reprogramming, device retesting should be 
strongly considered in patients receiving it. In cases where intraoperative DFT is ≤15 J, 
however, ICD retesting may not be required since the drug's impact on defibrillation energy 
safety margin is small with modern ICDs33. It should be noted, however, that this may not apply 
to patients with reduced (<20%) left ventricular ejection fraction (LVEF) since those patients 
were excluded from the study33, a substantial proportion of ICD recipients in general. Although 
several variables, including LVEF, have been shown to influence intraoperative DER23, there are 
no specific discriminators that can adequately predict which patients are expected to have high 
or low DER. Foregoing testing in patients with low LVEF (at our center we use an arbitrary 
cutoff value of <10%) may have the unintended consequence of possible device failure among 
patients at potentially greater risk of developing spontaneous VT/VF and for whom repeated 
unsuccessful   shocks   are   more   likely   to   lead   to   post-shock   pump   failure34-37.              
            As for testing at the time of ICD generator replacements, in addition to confirming 
proper integrity of the chronic leads38, we recommend defibrillation testing unless there had been 
appropriate therapies against VF in the near past and no evidence of substantial progression in 
the patient's cardiac disease and/or the addition of drugs (e.g., amiodarone) that may adversely 
raise DER. In clinically stable patients whose devices are not being replaced and who have not 
received any successful therapies against VF for a period of time, defibrillation testing might be 
reasonable albeit there is limited data regarding its usefulness28. 
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How To Test and the Impact of Testing                                                  
            Prior to defibrillation testing, adequate sensing (>5 mV) and pacing (<1 V) parameters 
and   electrical   integrity   (connections)   between   the   leads   and   pulse   generator   should   be 
determined and recorded. And assuming no contraindications (Table  1), with the patient 
comfortably sedated, VF is induced (through a variety of methods) with the following goals: (1) 
assure proper sensing and detection (and in case of first-shock failures, redetection) of VF; and 
(2) establish DER, based on which the device is then optimally programmed. 
Table 1. Contraindications to Intraoperative ICD Testing
*Unless there is no thrombus on transesophageal echocardiography. †Especially in patients with 
anticipated high defibrillation energy requirement (increasing the likelihood of needed external 
shock). ‡The best timing is uncertain, but we generally wait 4 to 6 weeks. ¶ We use a cutoff of 
≤10% ejection fraction; others have used <20%33.
Indian Pacing and Electrophysiology Journal (ISSN 0972-6292), 7(3): 166-175 (2007)Luis A. Pires, “Defibrillation Testing of the Implantable Cardioverter Defibrillator:           169 
When, How, and by Whom?”
            There are two broad categories of defibrillation testing: defibrillation threshold (DFT) 
and defibrillation safety margin (DSM). The DFT, defined as the lowest amount of energy 
capable of terminating an episode of induced VF, is most commonly determined through a step-
down method (i.e., successive lowering of shock strength). Because success of defibrillation is 
probabilistic, a true DFT cannot be established with certainty. For this reason plus the potential 
risk of repeated inductions of VF and defibrillations36,37, determining a DFT is now rarely used 
clinically except for research purposes28,39. In clinical setting, the goal of ICD testing is to 
determine an energy level that has a reasonable chance of success against spontaneous VT/VF 
events. This can be established by confirming a simple DSM, defined as an energy level capable 
of terminating one or more (generally two) episodes of induced VF and low enough to be at least 
≥10 J less than the device's maximum output16-18. This 10 J "safety margin", achievable in nearly 
all patients with modern ICDs16-18,28,39,40, has long been a common practice41 because patients 
with elevated DER (and monophasic devices) were thought to have a higher mortality rate42-44. 
With modern, biphasic devices, elevated DER has not been shown to adversely impact patient 
survival45,46. Nonetheless, though the required magnitude of the safety margin energy is 
uncertain and debated47, its establishment and incorporation in ICD programming allows for 
uncertainties in the DER requirement over time due to factors such as the addition of 
antiarrhythmic drugs, progression of cardiac disease, acute coronary events, and electrolyte 
changes.
               The confirmation of a single defibrillation success at 10-15 J (with devices with 
maximum outputs of 30-35 J) predict successes with stronger (20-30 J) shocks with a nearly 
100% accuracy16-19. Repeat testing at the same or lower energy levels does not seem to be 
clinically important and in our laboratory we follow a simple testing protocol: we test once at 11 
or 15 J depending on the device's maximum output (Figure 1); and if the first shock fails, a 
second shock of 10 J greater (21 or 25 J) is delivered (Figure 2). If the second shock fails, after 
reconfirming proper lead positions, we would then change shock polarity and tilt (StJude 
devices) and repeat the process. With an adequate programmed safety margin (generally ≥10 J), 
the first shock success rates against spontaneous VT/VF episodes range from 83% to 93%16-19,22, 
suggesting that defibrillation failures for spontaneous VT/VF may be due to factors (e.g., heart 
disease progression) not present at the time of intraoperative ICD testing. Therefore, it is not 
surprising that rigorous intraoperative testing may not necessarily translate into a fail-safe device 
therapy19,34,35
Figure 1: From top to bottom: atrial electrograms, ventricular electrograms, and marker channel. 
AS and VS indicates, respectively, atrial sensing and ventricular sensing. Shows an episode of 
induced ventricular fibrillation (dotted arrow) followed by a single successful 11 J shock (arrow) 
delivered by a 31 J output device. 
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Figure 2: From top to bottom: atrial electrograms, ventricular electrograms, and marker channel. 
The tracing is continuous (top to bottom panel). Shows an episode of induced ventricular 
fibrillation (dotted arrow) followed by a failed 15 J shock (arrow), followed by a second 
successful 25 J shock (open arrow) delivered by a 35 J output device. AS and VS indicates, 
respectively, atrial and ventricular sensing.
            Despite a surge in the use of ICDs, there has been limited data on the impact of ICD 
testing on patient outcome, in terms of both defibrillation success against spontaneous VT/VF 
events and patient survival19,22. When comparing the outcome of ICD recipients who underwent 
DFT, DSM and no testing at the time of implantation, we recently reported similar success of 
ICD therapies and sudden-death-free survival among the three groups, however, overall survival 
was significantly worse in the no-testing group but similar in the DFT and DSM groups19. The 
comparable survival rates in the DFT and DSM tested groups are important given that for many 
years now DSM testing has replaced DFT testing in clinical settings. The higher mortality in the 
no-testing group probably reflected the inclusion of sicker patients, and not the result of device 
therapy failure19. But since we could not confirm the specific causes of death in all cases, in the 
absence of prospectively obtained corroborating data we recommended against abandoning 
testing altogether, in line with other investigators22.                                           
            The ICD's primary function is to abort would-be fatal tachyarrhythmic events. Despite its 
phenomenal efficacy in terminating spontaneous VT/VF events, the ICDs protection against 
sudden   death   is   not   absolute19,34,35,48.   With   rare   exceptions49,   device   malfunctions   very 
infrequently account for sudden death in ICD recipients34,35. Often such deaths are the result of 
an acute cardiac (e.g., acute myocardial infarction) or non-cardiac (e.g, vascular rupture) process 
in the setting of a normally functioning ICD - factors that cannot be anticipated or tested for at 
the   time   of   implant34,35.                                                                          
Who   Should   Test                                                                                    
            ICD testing has always been the domain of cardiac electrophysiologists, beginning with  
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epicardial devices and later with the advent of first-generation transvenous devices, both of 
which were implanted by cardiac surgeons. In light of recent proposal sanctioning alternative 
training pathways in device implantation21, and heavy industry promotion, device testing 
(usually DSM) is now also performed by non-electrophysiologists. Whereas operator volume 
may impact patient outcome50, there exists no data on the safety and outcome of patients treated 
by  non-electrophysiologists,   making   specific   recommendations   as   who   should   test  ICDs 
problematic. Nonetheless it should be noted that non-electrophysiologists are not expected to 
participate in implantation of devices in patients with documented VT/VF (i.e., secondary 
prevention) who may be at greater future risk and, therefore, for whom careful testing is 
important to assure proper device function. Moreover, non-electrophysiologists, who may have 
suboptimal training in defibrillation, must be fully aware of patient and device specific factors 
that influence defibrillation success and proper troubleshooting methods to insure successful 
implantation in each case40. When there is sufficient doubt about the outcome, testing should be 
left to an experienced electrophysiologist.
Figure 3: A suggested approach to intraoperative ICD testing. See text for details.
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Conclusions
            With current ICDs, successful device implantation (i.e., a DER energy allowing for a ≥10 
J programming safety margin), determined through a single test and one episode of induced VF, 
can be expected in nearly all patients. Since such minimal testing rarely results in adverse events 
and there are no prospective data on the outcome of ICD recipients whose devices are not tested 
intraoperatively, we feel that, in the absence of contraindications, a minimum of testing is still 
appropriate (Figure 3). Certainly we do not believe testing should be abandoned to simply 
facilitate more device implantations by non-electrophysiologists who may be in some cases 
uncomfortable with defibrillation testing.
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